DaVita (NYSE:DVA) Price Target Lowered to $133.00 at TD Cowen

DaVita (NYSE:DVA) had its target price trimmed by TD Cowen from $154.00 to $133.00 in a research note released on Monday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

DVA has been the subject of a number of other research reports. Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Monday. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Zacks Research downgraded DaVita from a “hold” rating to a “strong sell” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Finally, Truist Financial set a $140.00 price objective on DaVita in a report on Tuesday, October 14th. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, DaVita has a consensus rating of “Reduce” and an average price target of $148.00.

DaVita Trading Down 0.0%

DaVita stock opened at $119.00 on Monday. The company has a market cap of $8.40 billion, a P/E ratio of 12.26, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13. DaVita has a 1-year low of $115.39 and a 1-year high of $179.60. The company has a fifty day simple moving average of $130.42 and a 200 day simple moving average of $136.41.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The business had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the business posted $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, equities research analysts forecast that DaVita will post 10.76 EPS for the current year.

Institutional Trading of DaVita

Several hedge funds and other institutional investors have recently modified their holdings of DVA. Man Group plc boosted its holdings in shares of DaVita by 1,608.6% during the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after buying an additional 269,081 shares during the period. Norges Bank bought a new stake in shares of DaVita during the 2nd quarter worth about $32,986,000. Doma Perpetual Capital Management LLC boosted its holdings in shares of DaVita by 172.3% during the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after buying an additional 182,476 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of DaVita during the 2nd quarter worth about $21,554,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of DaVita by 132.1% during the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after buying an additional 150,318 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.